A Randomized, Open-Label, Single-Dose, 3-Period Crossover, Comparative Study of a Modified Formulation of Vabicaserin (SCA-136) Versus the Reference Formulation in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs Vabicaserin (Primary)
- Indications Depressive disorders; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Wyeth
- 11 Sep 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 11 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Aug 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.